Skip directly to content

What are we doing

What are we doing 

In its first stage, CEPM’s research will focus on the field of oncology, specifically lung and breast cancers, seeking to validate, at the highest industry standards, new technology platforms for molecular diagnostics based on next-generation sequencing and to discover novel therapeutic targets and disease mechanisms at the molecular level.

During the development and progression of cancer, neoplastic cells acquire a series of genetic changes that result in drastic modifications both in how the cell responds to its environment and in the cell dynamics itself. The advance of genomic technologies and next generation sequencing have produced a wealth of information and provided substantial insights into the pathogenesis of disease. Especially in cancer, precision medicine is related with how these tools have been exceptionally useful for identifying novel signal transduction pathways, with a great potential for the discovery of new biomarkers and therapeutic targets. We understand personalized medicine, as the translation of these findings into a breakthrough in the understanding of cancer biology and care of cancer patients, however this remains a major challenge.

In our Center we have in place all the computational tools, high throughput sequencing technology and bioinformatics and cell biology techniques needed to understand cancer biology, from genomics to cell signaling. We also want to contribute to medicine, looking for ways to make the knowledge of cellular and molecular biology of cancer generated in our laboratories useful for patients with cancer. We are working on moving our research from the bench to the bedside.